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Abstract
Background: Tumor immune responses are first generated and metastases often begin in tumor sentinel lymph
nodes (TSLN). Therefore, it is important to promote tumor immunity within this microenvironment. Mifepristone
(RU486) treatment can interfere with cortisol signaling that can lead to suppression of tumor immunity. Here, we
assessed whether treatment with RU486 in conjunction with an intratumor injection of Ad5IL-12 vector (a
recombinant adenovirus expressing IL-12) could impact the TSLN microenvironment and prostate cancer
progression.
Methods: The human PC3, LNCaP or murine TRAMP-C1 prostate cancer cell lines were used to generate
subcutaneous tumors in NOD.scid and C57BL/6 mice, respectively. Adjuvant effects of RU486 were looked for in
combination therapy with intratumor injections (IT) of Ad5IL-12 vector in comparison to PBS, DL70-3 vector, DL70-3
+ RU486, RU486 and Ad5IL-12 vector treatment controls. Changes in tumor growth, cell cytotoxic activity and
populations of CD4
+/FoxP3
+ T regulatory cells (Treg) in the TSLN were evaluated.
Results: Treatment of human PC3 prostate xenograft or TRAMP-C1 tumors with combination Ad5IL-12 vector and
RU486 produced significantly better therapeutic efficacy in comparison to controls. In addition, we found that
combination therapy increased the capacity of TSLN lymphocytes to produce Granzyme B in response to tumor
cell targets. Finally, combination therapy tended towards decreases of CD4
+/FoxP3
+ T regulatory cell populations
to be found in the TSLN.
Conclusion: Inclusion of RU486 may serve as a useful adjuvant when combined with proinflammatory tumor
killing agents by enhancement of the immune response and alteration of the TSLN microenvironment.
Background
Prostate cancer is one of the leading causes of death in
men and has not been curable once it has metastasized
beyond the local prostate gland [1]. This poor effect of
current therapy on metastases could be the result of
immunosuppressive conditions found in tissue microen-
vironments where metastatic cancer cells migrate
including the TSLN. The TSLN is defined as the lymph
node to first receive lymphatic drainage from the pri-
mary tumor site and is the first lymphoid organ that
can respond to tumor challenge [2]. In patients, the sta-
tus of the TSLN is one of the most significant predictors
of overall survival for most clinical stage I/II solid
tumors [3,4]. An immune phenotype in which suppres-
sive cytokines are predominantly produced by Treg cells
amongst TSLN cells is usually associated with failure to
prevent tumor metastases [5]. Importantly with regard
to various immune-therapeutic interventions, Treg
populations have been shown to possess a capacity for
plasticity and can be converted from a suppressive to
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[6,7]. Therefore, novel therapies that override TSLN
immunosuppression may restore effective tumor
immunity.
We have previously used a recombinant adenovirus
vector expressing the IL-12 cytokine (Ad5IL-12) in com-
bination with mitotane, a drug that transiently sup-
presses cortisol production, to enhance the activity of
t h ev e c t o ra n dp r o d u c em o r es u c c e s s f u lt h e r a p yo f
experimental prostate cancers in mice [8]. Cortisol can
act on lymphocytes and dendritic cells (DC) to suppress
the expression of proinflammatory cytokines and costi-
mulatory molecules, factors that have been shown to be
important for the generation of immune responses
against tumors [9]. This study indicated that cortisol
can contribute to defects in immune function that allow
tumor escape. Because mitotane has an associated toxi-
city when used in treatment, we decided to test the
effects of cortisol receptor blockade using the drug mife-
pristone (RU486). Mifepristone is a progesterone analo-
gue that can act as an antagonist for the glucocorticoid
receptor (GR) [10]. Therefore, we examined RU486
treatment in combination with the Ad5IL-12 vector to
determine if this combination could similarly influence
(as mitotane treatment) prostate cancer progression.
Therapies incorporating combinations of adenovirus
vectors with various immune stimulatory agents have
been shown to produce better therapeutic outcomes
[11-13]. Given that RU486 is an approved pharmaceuti-
cal and affect pathways of homeostatic regulation, we
sought to evaluate whether it would also be useful as an
immunological adjuvant in cancer therapy.
Factors that influence the tissue microenvironment of
the TSLN include the production of immunosuppressive
cytokines. One of the most important suppressive cyto-
kines controlling immune response is IL-10. IL-10 has
been shown to generally suppress T cell immune
responses and elevated levels of this cytokine have been
detected in the serum of prostate cancer patients com-
pared to normal healthy controls [14]. Tumor infiltrat-
ing lymphocytes isolated from prostate cancers have
significantly higher IL-10 expression than T lymphocytes
from peripheral blood, indicating IL-10 can influence
cells in the tumor microenvironment and immune
response [15]. Another prominent inhibitory cytokine,
transforming growth factor-beta (TGF-b) can be pro-
duced by prostate cancer cells and has been shown to
inhibit prostate tumor immunity [16]. TGF-b has a
negative impact on immune function where it has been
shown to suppress T cell activation and chemotaxis, as
well as to inhibit DC maturation and function [17].
Additionally, studies have demonstrated an inverse cor-
relation to survival when higher levels of TGF-b are
detected in the serum or produced by tumor cells iso-
lated from prostate cancer patients [18,19].
Importantly, cortisol can induce the production of
both suppressive cytokines (IL-10 and TGF-b)a n d
could orchestrate hormonal control upon immune
response within the TSLN microenvironment. In asso-
ciation to human studies, a dysregulated diurnal cortisol
cycle was found to correspond to lower 5 year survival
outcomes for breast cancer patients, supporting an
importance of sustained cortisol levels to poorer clinical
outcomes [20]. In addition as cortisol can control the
production of IL-10 and TGF-b,t h e s ec y t o k i n e sh a v e
been linked to the establishment of immune suppression
in the tumor microenvironment by aiding in the expan-
sion of FoxP3
+ regulatory T cells (Treg) [21-23]. Treg
cells have been shown to negatively affect tumor immu-
nity as the depletion of CD4
+CD25
+FoxP3
+ Treg from
tumor tissue and the TSLN has been shown to facilitate
tumor rejection [24-26]. Therefore, it is possible that
therapies affecting cortisol response could downregulate
Treg activity in the TSLN and aid in the generation of
effective tumor immunity.
In this report, we demonstrate experimental prostate
tumors benefit from the inclusion of RU486 treatments
in combination with IT injection of Ad5IL-12 vector.
We find that this combination therapy has a greater
attenuating effect on the growth of both human andro-
gen-independent PC3 xenograft tumors in NOD.scid
mice as well as TRAMP-C1 tumors formed in C57BL/6
mice. With the addition of mifepristone treatment to
the Ad5IL-12 vector, cytotoxic activity in the TSLN is
enhanced. These results indicate that the inclusion of
RU486 in a proinflammatory-based prostate cancer
immunotherapy can favorably alter the TSLN microen-
vironment to improve treatment efficacy.
Materials and methods
Mice and tumor cell lines
Six- to eight-week old male NOD.scid and C57BL/6
mice were obtained from the Jackson Laboratory (Bar
Harbor, MD) and bred in the animal facilities at TPIMS.
All work was done according to TPIMS guidelines for
animal use and care. The TPIMS Institutional Animal
Care and Use Committee provided approval (TPI-08-02)
that covers the ethical use of animals in experimentation
and all experimental research on animals followed inter-
nationally recognized guidelines. The human prostate
cancer cell line PC3 was grown in Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10% fetal
bovine serum (FBS), 100 μg/ml streptomycin and 100
IU/ml of penicillin. The androgen-dependent LNCaP
cells were additionally supplemented with 10
-8 Md i h y -
drotestosterone. TRAMP-C1 tumor cells were passaged
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gen-independent growth for use in this study. All cell
lines were obtained from American Type Culture Col-
lection (Manassas, VA).
Establishment of tumor and treatment protocol
The human PC3, LNCaP or murine TRAMP-C1 pros-
tate cancer cell lines were used to generate subcuta-
neous tumors in NOD.scid and C57BL/6 mice. Two
m i l l i o nt u m o rc e l l si n5 0μl of PBS were mixed with 50
μl of matrigel and injected subcutaneously (SC) in the
right hind flank of animals. Intratumor injections (IT)
were given with a 5 × 10
8 pfu dose of adenovirus vec-
tors in 50 μl volumes of PBS using a 26-gauge needle
when palpable tumors formed (approximately 3 weeks).
Tumor growth was monitored weekly by measurment in
two dimensions using a caliper and volumes calculated
assuming a prolate spheroid tumor mass as previously
described [27]. Mifepristone/RU486 [17b-hydroxy-11b-
(4-dimethylaminophenyl)-17a-1-propyl-estra-4,9-dien-3-
one] catalog M8046 was purchased from Sigma-Aldrich
(St. Louis, MO). For use in intraperitoneal administra-
tions (IP), 200 μl volumes of microcrystalline RU486 (25
μg/g of weight) were freshly prepared in sterile PBS as
previously described [28].
Adenovirus vectors
The construction of the Ad5IL-12 and the DL70-3 ade-
novirus type 5 vectors (Ad5) used in this study are pre-
viously described [27]. The Ad5IL-12 vector is a
replication incompetent recombinant adenovirus type 5
(Ad5) that encodes the p35 subunit of IL-12 in the E1
region and the p40 subunit in the E3 region of the Ad5
virus genome. The DL70-3 control Ad5 vector is a
replication incompetent adenovirus depleted of E1
region sequences and expresses no transgene. All vec-
tors used in this study were propagated in 293 cells and
purified on cesium chloride gradients as previously
described [29].
TSLN Granzyme B measurement
The mouse granzyme B ELISA kit used to measure
granzyme B production from isolated TSLN lympho-
cytes was supplied by eBIOSCIENCE (San Diego, CA).
TSLN cells were prepared from individual mice bearing
TRAMP-C1 tumors from each treatment group (PBS,
RU486, DL70-3, Ad5IL-12 and Ad5IL-12 + RU486) at
the end of 7 days (the endpoint of RU486 therapy) and
incubated for 24 hrs with irradiated TRAMP-C1 cells as
targets. 1 × 10
6 TRAMP-C1 irradiated target cells (3000
r cumulative dose) were cultured alone or co-cultured
with 1 × 10
6 TSLN cells at 37°C in 24-well tissue cul-
ture plates in a volume of 500 μl of complete DMEM
media. At the end of this incubation period, superna-
tants were collected and analyzed for granzyme B con-
tent as per the manufacturer’s instructions.
Flow Cytometry
Characterization by flow cytometry analysis of cell sur-
face expression of Ly49C and CD4 on TSLN lympho-
cytes was performed with FITC-labeled anti-Ly49C and
anti-CD4 mAbs. For CD25 detection, an APC-labeled
anti-CD25 mAb was used. For intracellular detection, a
PE-labeled anti-FoxP3 mAb was used. All antibodies
and isotype controls were purchased from BD Bios-
ciences (San Diego, CA). All analysis was performed on
a FACSCalibur flow cytometer (Becton Dickinson,
Mountain View, CA).
Statistics
Statistical analysis was performed using the STATVIEW
4.5 program from Abacus Concepts (Berkeley, CA) by
Student’s t-test for final determination of significance.
Results
RU486 augments antitumor activity of Ad5IL-12 in PC3
xenograft model
Given that RU486 inhibits androgen signaling, we began
our studies on androgen-independent human prostate
cancer cell line PC-3 tumors formed subcutanously in
NOD.scid mice. As shown in Figure 1, both the mono-
therapy and combination therapy by IT administration of
the Ad5IL-12 vector resulted in statistical significant
attenuation of PC3 tumor growth compared to control
treatments at the 8-week time point (two-tailed t-Test;
p < 0.05). Ad5IL-12 vector treated mice had an approxi-
mate 5-fold greater reduction in PC3 tumor growth in
comparison to the control DL70-3 adenovirus vector as
well as to the PBS controls (668 ± 87 mm
3 versus 3163 ±
802 mm
3 and 3394 ± 707 mm
3, respectively). These data
were in agreement with our previous findings using this
model system in which tumor regression was shown to
be principally NK cell-dependent [8].
Here, addition of RU486 to the Ad5IL-12 vector led to
even further tumor inhibition. Combination therapy
resulted in mice with average tumor volumes of 298 ±
120 mm
3 at the 8 week time point, representing an
additional 2.24-fold reduction in tumor mass when com-
pared to the Ad5IL-12 vector treatment alone (p =
0.029) and a 6.70-fold difference against the RU486
treatment alone (p = 0.010). While the administration of
RU486 alone did appear to slow tumor growth some-
what in comparison to the DL70-3 and PBS controls,
this effect did not reach statistical significance over the
time course analyzed (the tumor volume for RU486
treatment at 8 weeks averaged 1989 ± 307 mm
3).
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the growth of human androgen-dependent LNCaP
xenograft tumors
We next investigated tumor treatments of androgen-
dependent LNCaP xenograft tumors. As shown in Fig-
ure 2, statistical differences in tumor growth were
demonstrated, with both Ad5IL-12 vector or RU486
treatment resulting in an approximate 3-fold reduction
in tumor mass compared to controls (p < 0.05). Tumor
volumes averaged 1073 ± 226 mm
3 in Ad5IL-12 vector
treated mice in comparison to 3197 ± 600 mm
3 for
DL70-3 vector and 3353 ± 532 mm
3 for PBS treatment.
Unlike the limited effect seen for RU486 treatment
against PC3 androgen-independent tumors, the mife-
pristione treatment regimen here alone was able to sig-
nificantly attenuate LNCaP tumor growth. Also in
contrast to the effect for combination therapy seen
against PC3 tumors, the combined action of Ad5IL-12
and RU486 treatment did not produce a statistically sig-
nificant better therapeutic effect against tumor than
either treatment alone. At the 8 week time point, tumor
volumes averaged 1284 mm
3 for RU486 treatment com-
pared to 1073 mm
3 for Ad5IL-12 alone and 1015 mm
3
for the Ad5IL-12/RU486 combination treatment. For
LNCaP tumors, the RU486 treatment regimen alone
produced similar attenuation of tumor growth as that of
Ad5IL-12 IT treatment. Our results support earlier
findings for RU486 effects on LNCaP tumors but also
indicate that the systemic delivery of RU486 (IP) can
affect tissue-localized responses against an androgen-
dependent tumor.
Combination Ad5IL-12 + RU486 therapy in immune
competent C57BL/6 mice produces significantly greater
attenuation of TRAMP-C1 tumor growth than either
treatment alone
Because the use of NOD.scid mice bearing human xeno-
graft prostate tumors does not model treatment effects
on a fully intact immune system, we next set out to
determine what impact combination therapy would have
against established TRAMP-C1 tumors using immune
competent C57Bl/6 mice. As shown in Figure 3A, treat-
ment with a single IT injection of Ad5IL-12 vector
caused significant reduction of TRAMP-C1 tumor
growth (with much greater reductions) in comparison to
control treatments (PBS, DL70-3 and RU486). Tumor
volumes averaged 386 ± 77 mm
3 for Ad5IL-12 treat-
ment in comparison to 4204 ± 604 mm
3 for PBS, 3661
± 1049 mm
3 for DL70-3 and 3194 ± 733 mm
3 for
RU486 treatment. In these immunocompetent mice,
RU486 significantly augmented the effects of Ad5IL-12
vector treatment with an approximate 2.9-fold attenua-
tion of tumor growth being evidenced in comparison to
the Ad5IL-12 vector treatment alone (Figure 3B).
Tumor volumes averaged 386 ± 77 mm
3 for Ad5IL-12
Figure 1 Intratumoral injection with Ad5IL-12 vector and 1
week treatment with RU486 synergistically attenuates the
growth of human PC3 tumors. Xenograft tumors established SC in
NOD.scid mice were treated at week 3 by IT injection with 50 μlo f
PBS containing 5 × 10
8 pfu of Ad5IL-12 (filled squares) or control
DL70-3 vector (empty squares) or PBS alone (empty circles). In
addition, another set of mice were treated with Ad5IL-12 IT
injection and given daily IP injections of RU486 for 7 days (black
triangles). Data points are expressed as the mean ± SE. n = 8 for
each data point. *indicates statistical significance of P < 0.05 for
Ad5IL-12 + RU486 treatments alone compared to controls. Tumor
volumes measured at 8 weeks were 3394 ± 87 mm
3 for PBS, 3163 ±
87 mm
3 for DL70-3, 1989 ± 307 for RU486, 668 ± 87 mm
3 for
Ad5IL-12 and 298 ± 120 mm
3 for Ad5IL-12 + RU486 treatment
groups.
Figure 2 Intratumor injection with Ad5IL-12 or 1 week
treatment with RU486 attenuates the growth of human LNCaP
tumors. Xenograft tumors established in NOD.scid mice were
treated at week 3 by IT injection with 50 μl of PBS containing 5 ×
10
8 pfu of Ad5IL-12 (filled squares) or the control DL70-3 vector
(empty squares) or PBS alone (empty circles). In addition, another
set of mice were treated with Ad5IL-12 IT and given daily IP
injections of RU486 for 7 days (black triangles). Data points are
expressed as the mean ± SE. n = 8 for each data point. *indicates
statistical significance of P < 0.05 for Ad5IL-12 + RU486 treatments
alone compared to controls. Tumor volumes measured at 8 weeks
were 3353 ± 532 mm
3 for PBS, 3197 ± 600 mm
3 for DL70-3, 1284 ±
350 for RU486, 1073 ± 226 mm
3 for Ad5IL-12 and 1015 ± 321 mm
3
for Ad5IL-12 + RU486 treatment groups.
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3 in RU486 +
Ad5IL-12 combination therapy. Statistically significant
differences for effects on tumor growth (p < 0.05) were
reached by the 8-week time point in comparison
between the Ad5IL-12 vector alone versus combination
Ad5IL-12+RU486 treatment indicating inclusion of
RU486 improved therapeutic efficacy. Moreover,
combination therapy produced a 24-fold greater
attenuation of tumor growth in comparison to the
RU486 treatment alone. This finding is striking consid-
ering here that RU486 treatment appeared to have no
significant effect on TRAMP-C1 tumor growth alone.
While no cures were produced by treatment from any
control animals, 3 of 8 mice receiving the combination
therapy had complete resolution of their tumors. As the
TRAMP-C1 cells used in tumor formation were weaned
off their androgen-dependency, these results suggest
that RU486 treatment can better enhance the therapeu-
tic effects by a proinflammatory cancer agent through
immune-mediated mechanisms in an immune compe-
tent host.
TSLN cells isolated following combination Ad5IL-12/
RU486 treatment generate enhanced granzyme B levels
against TRAMP-C1 tumor cell targets
In tumor models involving subcutaneous flank implanta-
tion similar to the one used in these studies, the popli-
teal lymph node serves to provide lymphatic drainage
and also contains the highest number of tumor-specific
effector T cells [30]. To investigate possible mechanisms
involved in the ability of RU486 to enhance efficacy of
Ad5IL-12, we compared granzyme B levels produced
from isolated popliteal lymph node cells (the TSLN) co-
cultured for 24 hrs with irradiated TRAMP-C1 tumor
cells as targets. Granzyme B is an important effector
molecule of cell-mediated immunity correlating to effec-
tive tumor immune response [31] and measurement of
its levels correlate well to total cellular cytotoxicity [32].
TSLN cells were isolated from individual animals with
established TRAMP-C1 tumors following treatment. As
shown in Figure 4, granzyme B levels in Ad5IL-12-trea-
ted mice were enhanced in comparison to the DL70-3,
RU486 and PBS control treatment groups. Granzyme B
levels averaged 337 pg/ml in Ad5IL-12 treated mice
compared to 119 pg/ml for DL70-3, 32.8 pg/ml for
RU486 or 5.5 pg/ml for PBS controls. An additional
2-fold increase in granzyme B production could be pro-
duced by (averaging 779 pg/ml) was found for combina-
tion RU486 + Ad5IL-12 vector treatment. Given the
importance of the TSLN in tumor response [5], this
additional increase in granzyme B production indicates
that improved cytolytic activity can be facilitated by the
addition of RU486 treatment to the Ad5IL-12 vector.
Ly49C
+ NK cells are expanded by Ad5IL-12 therapy but
cannot be further enhanced by combination therapy
We have previously reported that Ad5IL-12 therapy eli-
cits antitumor effects through an NK cell-dependent
response [8]. Accordingly, we sought to determine
whether any enhancement in efficacy by the inclusion of
RU486 was related to modulation of NK cell numbers at
Figure 3 Intratumoral injection with Ad5IL-12 vector and 1
week treatment with RU486 synergistically attenuates growth
of TRAMP-C1 tumors. (A) TRAMP-C1 tumors established in C57BL/6
mice were treated at week 3 following tumor cell inoculation by IT
injection with 50 μl of PBS containing 5 × 10
8 pfu of Ad5IL-12 (filled
squares) or control DL70-3 vector (empty squares) or PBS alone
(empty circles). Data points are expressed as the mean ± SE. n = 8
for each data point. *indicates statistical significance of P < 0.01 for
Ad5IL-12 compared to controls. (B) C57BL/6 mice treated with an
intratumor injection of Ad5IL-12 (black squares), or given an
additional daily IP injection with RU486 (black triangles) for 1 week
were compared. *indicates statistical significance of P < 0.05 for
Ad5IL-12 + RU486 compared to Ad5IL-12 alone. The ratio of cures
per number of treated animals is indicated. Tumor volumes
measured at 8 weeks were 4204 ± 604 mm
3 for PBS, 3661 ± 1049
mm
3 for DL70-3, 3194 ± 733 for RU486, 386 ± 77 mm
3 for Ad5IL-12
and 133 ± 53 mm
3 for Ad5IL-12 + RU486 treatment groups.
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was used to assess levels of Ly49C
+ cells from TSLN
isolated from TRAMP-C1 tumor bearing mice following
the end of the treatment cycle. In Figure 5, a representa-
tive group of animals from one of the flow cytometry
analyses is shown. In Ad5IL-12 treated mice, an approx-
imate 2-fold increase in the percentage of Ly49C
+ NK
cells was observed compared to DL70-3 controls (40.7%
compared to 21.3%, respectively). Here, the addition of
RU486 to Ad5IL-12 vector therapy did not increase the
number of NK cell numbers elicited any greater than
that of the Ad5IL-12 vector treatment alone. NK cell
percentages for Ad5IL-12 + RU486 versus the Ad5IL-12
vector remained similar suggesting that NK cells may
already be optimally expanded with Ad5IL-12 vector
treatment. While the DL70-3 vector treatment resulted
in an approximate 1.5 fold increase in the percentages
NK cells found in the TSLN in comparison to the PBS
control (21.3% compared to 14.2%, respectively), DL70-3
vector treatment had little overall impact on TRAMP-
C1 tumor growth. Other factors in addition to the
expansion of NK cells must account for the differences
in the tumor killing produced between the Ad5IL-12
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Figure 4 Granzyme B production from cells is additionally
enhanced following Ad5IL-12 and RU486 therapy. Granzyme B
levels were measured from isolated TSLN cells in TRAMP-C1 tumor
bearing C57BL/6 mice following experimental treatments. Assays
were performed in duplicate for each treated animal. Cumulative
data from 2 independent experiments are shown using a total of
n = 8 animals per each treatment group. *indicates statistical
significance of P < 0.05 for Ad5IL-12 + RU486 treatments alone
compared against all other treatment groups.
Figure 5 NK cell populations in the TSLN are increased by
Ad5IL-12 vector treatment. TRAMP-C1 tumors in C57BL6 mice
were treated with injection of PBS, DL70-3, or the Ad5IL-12 vector.
Another set of mice corresponding to each of these treatment
groups received an additional daily administration of RU486 IP for 1
week. At the end of treatment, TSLN were isolated and analyzed by
flow cytometry for their content of Ly49C
+ NK cells. A
representative dot plot is shown from one set of animals out of 3
separate experiments. Cumulative data from 3 flow cytometry
analyses demonstrated Ly49C expression percentages averaged 7.95
± 2.8 for PBS, 8.86 ± 2.7 for RU486, 11.94 ± 6.0 for DL70-3, 12.07 ±
4.7 for DL70-3 + RU486, 19.88 ± 9.9 for Ad5IL-12 and 21.33 ± 9.5 for
Ad5IL-12 + RU486 treatment groups; n = 6. TSLN lymphocytes from
two treated animals from each treatment were analyzed in each
flow cytometry experiment.
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expression on NK cells has been shown to be mediated
by IL-12 and could account for some of the enhanced
tumor killing response [33].
A trend towards decreases in regulatory T cells in the
TSLN is found following combination therapy with Ad5IL-
12 and RU486 in TRAMP-C1 tumor bearing C57Bl/6 mice
Regulatory T cells (Treg) have been implicated in the
down regulation of tumor immunity in the TSLN [5].
As impairment of Treg function may be conferred by
reductions in number, we evaluated the impact of com-
bination therapy on the Treg compartment in the TSLN
following completion of the experimental therapeutic
regimen. In Figure 6, a representative group of animals
from one of the flow cytometry analyses is shown. The
percentage of CD4
+Foxp3
+ T cells found in Ad5IL-12
treated mice were diminished in the TSLN in compari-
son to PBS and DL70-3 vector controls (1.0% versus
1.6% and 2.0%, respectively). An additional decrease in
Treg content could found when RU486 was used in
combination with the Ad5IL-12 vector versus the
Ad5IL-12 vector treatment alone (0.6% versus 1.0%).
Cumulative data of 6 animals in total from each treat-
ment group revealed a trend towards lower Treg pre-
sence in the TSLN for the Ad5IL-12 (1.75 ± 0.35%) and
Ad5IL-12 + RU486 (1.64 ± 0.36%) treatment groups in
comparison to all the other treatment groups including
the PBS (2.26 ± 0.27%) and DL70-3 (1.98% ± 0.18%)
controls. Together, these data suggest that Treg cells
may be influenced by cortisol in the TSLN and contri-
bute in part to suppression of tumor immunity.
Discussion
Mifepristone is a drug that has been previously
approved for the termination of pregnancy and its capa-
city to act as an antagonist fo rt h ep r o g e s t e r o n eh o r -
mone receptor. However, it can also work as an
antagonist for an additional array of hormone receptors
including those of estrogen, testosterone and cortisol.
Importantly, it has already been shown to have inhibi-
tory effects on the growth of both ovarian and breast
cancers in human clinical trials [34]. Because of the
potential capacity to block cortisol signaling, we thought
RU486 could act in addition as an immune modulatory
agent and serve as a possible adjuvant in prostate cancer
therapy. No reports for the effects of RU486 in combi-
nation with an immune stimulatory factor have yet been
described to our knowledge. Interestingly, RU486 has
been reported to impact cancer cachexia by blocking
Figure 6 Ad5IL-12 vector treatment of TRAMP-C1 tumors can
reduce percentages of CD4/Foxp3 Tregs found in the TSLN.
C57BL6 mice were treated with injection of PBS, DL70-3, or the
Ad5IL-12 vector while another set of mice corresponding to each of
these treatment groups received an additional daily IP
administration of RU486 for 1 week. At the end of this treatment,
draining TSLN were isolated from individual animals and analyzed
by flow cytometry for their content of CD4
+/Foxp3
+ T cells. A
representative dot plot is shown from one set of animals out of 3
separate experiments. Cumulative data from 3 flow cytometry
analyses demonstrated CD4/FoxP3 expression percentages averaged
2.27 ± 0.2 for PBS, 2.12 ± 0.3 for RU486, 1.98 ± 0.2 for DL70-3, 1.98
± 0.2 for DL70-3 + RU486, 1.75 ± 0.4 for Ad5IL-12 and 1.64 ± 0.4 for
Ad5IL-12 + RU486 treatment groups; n = 6. TSLN lymphocytes from
two treated animals from each treatment were analyzed in each
flow cytometry experiment.
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coprotein (ZAG) expression in adipose tissue [35]. ZAG
impacts the mobilization of fat stores and breakdown of
body fat supporting another indication for the inclusion
of RU486 in therapy. Thus, the use of RU486 in prostate
cancer therapy could have effects on cachexia, andro-
gen-dependent tumor growth and as an adjuvant in
immune response activation. In this study, we have
begun to address some of these considerations with
regard to immune response and androgen-dependency.
Here, we have been able to demonstrate that the addi-
tion of RU486 (mifepristone) in combination with intra-
tumor injection of Ad5IL-12 vector can enhance
prostate cancer therapeutic efficacy versus that of vector
therapy alone. The inclusion of RU486 may further
enhance tumor immunity within the TSLN through a
variety of factors. The addition of RU486 to Ad5IL-12
vector therapy enhanced tumor cytotoxicity as measured
by granzyme B production against TRAMP-C1 tumor
targets from isolated TSLN lymphocytes. In addition to
its effect on cytotoxicity, inclusion of RU486 in Ad5IL-
12 vector treatment appeared to lead to further subtle
decreases in regulatory CD4 T cell populations to be
recovered in the TSLN. Both of these effects would
appear to be advantageous towards inducing better
tumor immunity and protecting against the spread of
tumor cells into the draining TSLN. While most of the
anti-tumor effect is clearly the result of the proinflam-
matory response induced by the Ad5IL-12 vector, our
results indicate that additional cortisol blockade by
RU486 allows for and enhanced activation and perhaps
prolongation of both innate and adaptive tumor immune
responses.
It is clear that the effects observed on LNCaP tumors
in this study were mediated by RU486 antagonistic
interactions on androgen receptor. The use of mifepris-
tone has previously been shown to inhibit the growth of
LNCaP tumors formed in nude mice through interac-
tion with the androgen receptor (AR) because of a
unique AR-T877A mutation that is present in this can-
cer cell variant [36]. It is likely that RU486 may also
affect other prostate cancer cell types as well, as double
AR mutant metastatic prostate cancer cells containing
substitutions of L701H and T877A have been found
that use cortisol as a growth factor [37]. Thus, inclusion
of RU486 could provide additional benefit in cancer
therapy for some prostate tumors independent of its
effect on immune response as an adjuvant we have
found.
In what would appear to be a contra-indication for the
use of RU486 in therapy, glucocorticoids are often pre-
scribed to treat hormone refractory prostate cancers.
However, the beneficial effects for this therapy are tran-
s i e n ta n da r eo n l yf o u n dt oh e l pas m a l ls u b s e to f
patients (20 to 25% of all cases of disease) [38]. What
could account for this small percentage of tumors found
to be responsive to glucocorticoid treatment is the
observation that the glucocorticoid receptor (GR) is lost
in up to 85% of all prostate cancers during progression
[39]. Thus the beneficial effect of glucocorticoid therapy
m a yb el i m i t e dt oo n l yas m a l ls u b s e to fp a t i e n t s .F r o m
our results, it appears likely that the inclusion of RU486
(given during the therapeutic window of time) with an
immunostimulatory agent could be beneficial in the
treatment of most prostate cancer types but possibly
affecting each through different mechanisms.
Previous studies have reported on the use of an
Ad5IL-12 vector in experimental cancer therapy includ-
ing prostate cancer with promising results including the
ability to aide in the suppression of lung metastases
[40,41]. The anti-tumor activities of IL-12 are known
and include inducing NK cell activation and boosting
the generation of antigen-specific immune response.
The proinflammatory effect of IL-12 is more effective
when applied in local tumor therapy versus systemic
treatment due to its potential toxicity. The ability to
deliver RU486 systemically and influence the local
effects of IL-12 could limit some of the toxic effects of
IL-12 and offer a general strategy to aid in the activity
of other localized proinflammatory acting cancer agents.
Some studies have linked chronic inflammation to the
initiation of prostate cancer and even further have sug-
gested that Tregs can act in a protective manner against
the generation of cancer [42]. We suggest this phenom-
enon is a consequence of timing as it is possible that
chronic inflammation (and loss of control by Treg)
could be deleterious and aid in cancer during early
initiation events when genetic mutations can be
acquired. It is likely that at later stages, when mutations
have already been established, that removal of Treg and
inducing inflammatory conditions in the tumor would
be beneficial. In support of this idea, it has already been
shown that antitumor immunity in cancer patients is
enhanced by the elimination of Tregs [43] and an over-
abundance of tissue CD4 Tregs leads to additional dys-
functions in antigen-specific CD8 T cell responses [44].
Finally, cancer patients with demonstrated increases of
Treg in their circulation and an increased presence in
their tumor tissues have poorer clinical outcomes
[45,46].
Completion of a phase II clinical trial study using
RU486 on castration resistant prostate cancers revealed
limited benefit for this treatment [47]. Yet, this trial
revealed good tolerance for mifepristone treatments
especially in the elderly patient population studied with
no incidences of clinical adrenal insufficiencies were
reported. Similar low toxicity was witnessed for the
repeated use of RU486 in ovarian and breast cancer
Gabaglia et al. Journal of Translational Medicine 2010, 8:98
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The poor effects for RU486 in this previous prostate
cancer study could reflect the selected patient sensitivity
towards androgen alone. The ability of RU486 to influ-
ence immune response in conjunction with an immu-
nostimulatory agent was not explored. We believe
beneficial effect for this type of immune enhancement
could be noticed in therapeutic application and should
be tested. In our hands, RU486 treatment provided with
the Ad5IL-12 pro-inflammatory agent was able to pro-
vide additional benefit for the control of human PC3
tumors (using only innate NK response) and TRAMP-
C1 tumors (with a totally intact immune system and in
the presence of Treg).
Conclusion
Our results suggest that RU486 can be a clinically rele-
vant agent for use as an adjuvant in pro-inflammatory
cancer therapy and may help to override immunosup-
pressive conditions found within tumor microenviron-
ments. We believe these results support the further
development of combination therapy in cancer that
include RU486 as an adjuvant and merits consideration
for testing in human clinical trials.
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